BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology ResearchBusiness Wire • 12/09/25
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and CanadaGlobeNewsWire • 12/09/25
Watch 5 Bigwigs in December After Double-Digit Returns Past MonthZacks Investment Research • 12/08/25
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?The Motley Fool • 12/07/25
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025)Seeking Alpha • 12/06/25
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newbornsReuters • 12/05/25
These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?The Motley Fool • 12/05/25
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat TumorsBenzinga • 12/04/25
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)Business Wire • 12/04/25
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
30% of the S&P 500 Is Mag 7 Tech Stocks, but This ETF Refuses to Own a Single One24/7 Wall Street • 12/02/25
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025Business Wire • 12/01/25
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth BuildersThe Motley Fool • 11/30/25